Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro.

ABSTRACT:

Background

Glioblastoma represents a brain tumor with a notoriously poor prognosis. First-line therapy may include adjunctive Tumor Treating Fields (TTFields) which are electric fields that are continuously delivered to the brain through non-invasive arrays. On a different note, CUSP9v3 represents a drug repurposing strategy that includes 9 repurposed drugs plus metronomic temozolomide. Here, we examined whether TTFields enhance the antineoplastic activity of CUSP9v3 against this disease.

Methods

We performed preclinical testing of a multimodal approach of TTFields and CUSP9v3 in different glioblastoma models.

Results

TTFields had predominantly synergistic inhibitory effects on the cell viability of glioblastoma cells and non-directed movement was significantly impair

SUBMITTER: Cao Q 

PROVIDER: S-EPMC11015043 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature